Last reviewed · How we verify
US-Avastin®
At a glance
| Generic name | US-Avastin® |
|---|---|
| Sponsor | Shanghai Henlius Biotech |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects (PHASE1)
- A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. (PHASE1)
- Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects (PHASE1)
- Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers (PHASE1)
- A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
- COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US-Avastin® CI brief — competitive landscape report
- US-Avastin® updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI